MAYNARD - December 13, 2002 -- EXACT Sciences Corporation and Apogent Discoveries announced today that they have executed a licensing agreement regarding certain patents owned by Apogent relating to its Acrydite™ technologies. The license provides EXACT Sciences, and its partners, with the ability to manufacture and use Acrydite in EXACT Sciences' PreGen-Plus™ assay. PreGen-Plus™ is EXACT Sciences' proprietary fecal DNA assay to detect colorectal cancer in the average-risk population. Terms of the agreement were not disclosed.
"The execution of this license represents another step on our path to the commercialization of PreGen-Plus," commented Don Hardison, EXACT Sciences President and CEO. "The inclusion of the Acrydite technology in our PreGen-Plus assay provides us with the opportunity to continue to improve our technologies in preparation for commercialization, a process that we started last quarter upon the signing of our strategic partnership agreement with Laboratory Corporation of America(R) Holdings (LabCorp). We look forward to continuing this process, in conjunction with LabCorp, as we get ready to launch PreGen-Plus."
About EXACT Sciences Corporation
EXACT Sciences Corporation is an applied genomics company that has developed proprietary technologies that may be used for the early detection of several common cancers. EXACT Sciences has selected colorectal cancer as the first application of its technologies. Colorectal cancer is the most deadly cancer among non-smokers, and is curable if detected early. Despite the availability of colorectal cancer screening and diagnostic tests for more than 20 years, the rate of early detection of colorectal cancer remains low. EXACT Sciences believes its genomics-based technologies will enable early detection of colorectal cancer so that more people can be effectively treated. Founded in 1995, EXACT Sciences is based in Maynard, Mass. Detailed information on EXACT Sciences can be found on the World Wide Web at www.exactsciences.com.